The U.S. Federal Trade Commission filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER.
Twenty-six drug manufacturers were sued by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices.
As Allergan and AbbVie continue to move forward with their unification, a group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that the business combination will create a monopoly and harm competition.
